- Home
- INKT vs GOVX Comparison
INKT vs GOVX Comparison
Compare INKT & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- GOVX
- Stock Information
- Founded
- INKT 2017
- GOVX 2001
- Country
- INKT United States
- GOVX United States
- Employees
- INKT N/A
- GOVX N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- GOVX Health Care
- Exchange
- INKT Nasdaq
- GOVX Nasdaq
- Market Cap
- INKT 28.5M
- GOVX 23.8M
- IPO Year
- INKT 2021
- GOVX N/A
- Fundamental
- Price
- INKT $0.46
- GOVX $2.26
- Analyst Decision
- INKT Strong Buy
- GOVX Strong Buy
- Analyst Count
- INKT 2
- GOVX 5
- Target Price
- INKT $6.50
- GOVX $14.20
- AVG Volume (30 Days)
- INKT 43.7K
- GOVX 715.7K
- Earning Date
- INKT 11-14-2024
- GOVX 11-12-2024
- Dividend Yield
- INKT N/A
- GOVX N/A
- EPS Growth
- INKT N/A
- GOVX N/A
- EPS
- INKT N/A
- GOVX N/A
- Revenue
- INKT N/A
- GOVX $3,090,161.00
- Revenue This Year
- INKT N/A
- GOVX N/A
- Revenue Next Year
- INKT N/A
- GOVX $150.51
- P/E Ratio
- INKT N/A
- GOVX N/A
- Revenue Growth
- INKT N/A
- GOVX N/A
- 52 Week Low
- INKT $0.46
- GOVX $1.09
- 52 Week High
- INKT $1.90
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- INKT 15.27
- GOVX 44.80
- Support Level
- INKT $0.64
- GOVX $2.17
- Resistance Level
- INKT $0.67
- GOVX $2.50
- Average True Range (ATR)
- INKT 0.06
- GOVX 0.17
- MACD
- INKT -0.02
- GOVX -0.04
- Stochastic Oscillator
- INKT 0.00
- GOVX 18.33
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.